Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/8/2013

moderate in nature in both groups.

Financial OutlookAcelRx records as revenue the reimbursement received pursuant to the $5.6 million USAMRMC grant received in 2011.  To date, revenue from this grant has been the only source of revenue recognized by AcelRx and we have recorded revenues of $4.4 million through March 31, 2013. We expect the remaining $1.2 million to be recorded as revenue over the remaining life of the grant, which terminates on January 31, 2014.

We anticipate that research and development expenses for the remaining quarters of 2013 will be substantially lower than the $9.3 million reported for the first quarter of 2013 due to lower clinical development expenses associated with our NanoTab System and ARX-04 programs. These decreases in R&D will be partially offset by the work involved in the preparation of a New Drug Application for the Sufentanil NanoTab PCA System, expected to be submitted to the FDA in third quarter of 2013.  Additionally, AcelRx anticipates modest increases in 2013 in general and administrative expense due to costs associated with commercial preparations for the launch of the NanoTab System in the U.S. and expansion of its corporate infrastructure to support a commercial launch.  Total operating expenses for 2013 are anticipated to be modestly higher than they were in 2012.

Other income and expense in future periods is expected to include non-cash charges that result from the liability accounting related to the warrants we issued in connection with the PIPE financing completed in the second quarter of 2012.  The primary determinant of this charge is stock price change over each quarter and its impact on the Black-Scholes valuation of these warrants.  For this reason the impact in future periods is very difficult to predict and is not included in the Company's guidance.

AcelRx believes its current cash, cash equivalents and investments are sufficient to fund operations int
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
2. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
3. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
4. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
5. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
6. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
7. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. AcelRx Pharmaceuticals Provides Clinical Trial Updates
9. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
10. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- Emergency ... design, blended emergency medical training and response technologies, ... defibrillator) training from the Department of Homeland ... Reserve 81 st Regional Support Command ... contract includes nationwide CPR/AED/First Aid training. The Army ...
(Date:8/27/2014)... , Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that certain members of the ... Healthcare Conference to be held September 8-10, 2014 in ... , Chief Executive Officer and President, is scheduled to ... portfolio at 10:55 a.m. ET on Wednesday, September 10, ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... The American Brain Tumor Association is ... Research Fellowships and 2014-2015 Discovery Grant Awards. Through the ... the field with talented, bright young investigators who have ... effects, diagnosis and treatment of brain tumors. This year’s ... the potential to advance the understanding and treatment of ...
(Date:8/27/2014)... Albany, New York (PRWEB) August 27, 2014 ... published by Transparency Market Research "Ablation Technologies Market ... Technologies: Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - ... Forecast, 2014 - 2020," the global ablation technologies ... 2013 and is estimated to reach a market ...
(Date:8/27/2014)... Center for Leadership in Disability (CLD) has received ... Child Health Bureau of the Health Resources and ... Plan for Georgia, aimed at improving services for ... In preparing for this project, CLD worked with ... from across Georgia. The resulting plan addresses priorities ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5
... in the last one month in Deomali and its ... officer N Singh said today. // ,Singh ... war footing to bring the situation under control., ... claimed death of 20 people in 15 days and ...
... of Georgia say that even if the surgery has gone ... of cardiovascular disease// and possibly cancer for several weeks post-operatively. ... is that when bad things happen down the road, months, ... in the past, just attribute it to the natural course ...
... today said it has entered into an agreement with ... of Foot and Mouth Disease (FMD) vaccine developed by ... the agreement, we will produce and market the vaccine ... meet the requirements of the domestic market and if ...
... 6. Even as asthma patients from different parts of ... fish medicine, rationalists have stepped up their campaign against ... of rationalists, has again urged the Andhra Pradesh government ... 'drug' was based on 'superstition'. ,The Bathini family, ...
... activity of a protein called NFATc1 tends to cause ... treat osteoporosis //- HHMI investigator Gerald Crabtree and HHMI ... bone is constantly being formed and being broken down ... cells called osteoblasts replenish it. ,‘Ideally, ...
... illness, which was under-diagnosed till now was found to ... thought before//. Intermittent Explosive Disorder or Rage disorder is ... outbursts. This illness if left untreated may also lead ... ,Intermittent Explosive Disorder attacks are out of proportion to ...
Cached Medicine News:Health News:Well-Planned Surgeries Also Carry Health Risks 2Health News:Well-Planned Surgeries Also Carry Health Risks 3Health News:'Fishy' Medicine Stirs Controversy 2Health News:'Fishy' Medicine Stirs Controversy 3Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 2Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 3
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: